Evidence map›Paper›PMID 31098886›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2019

Is the trend of increasing use of patient-reported outcome measures in medical device studies the sign of shift towards value-based purchasing in Europe?

Miklós Weszl, Fanni Rencz, Valentin Brodszky

Abstract read
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Review
  14. Value-Based procurement for medical devices: A scoping review.Medical journal of the Islamic Republic of Iran · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Miklós WeszlDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, H-1093, Hungary. miklos.weszl@uni-corvinus.hu.ORCID http://orcid.org/0000-0001-8000-4367
Fanni RenczDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, H-1093, Hungary.ORCID http://orcid.org/0000-0001-9674-620X
Valentin BrodszkyDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, H-1093, Hungary.ORCID http://orcid.org/0000-0002-6095-2295

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe recent update of the European Union's (EU) regulation on public procurement has created new opportunity for progress in the purchasing of medical devices by shifting towards focus on value from one purely on price. Patient-reported outcome measures (PROMs) may serve as additional tools for manufacturers to demonstrate value beyond traditional metrics of safety and performance and to differentiate their products in a market of increasing competition. The aim of our study was to investigate the extent to which PROMs are included in registered device studies in the EU and interpret the results in the context of the purchasing of medical devices.

methodsTwelve device groups were searched in clinical trial registries to determine the frequency distribution of PROMs in related studies.

resultsResults indicate that clinical studies of the selected device categories are done predominately in the western EU nations and are increasingly including PROMs. In the United Kingdom 121 (65%) study, out of 186 included PROMs, and in Germany, 92 (52%) out of 178 between 1998 and 2018. Few device studies were done in the Central and Eastern European region, and out of 76 studies 27 (35%) included PROMs. Since there is no requirement to include PROMs in device studies for regulatory purposes, it seems probable that their increasing use is driven by competitive market pressures.

conclusionThe trend of increasing use of PROMs might be driven by the demand of purchasers to demonstrate value of devices, but is manifested at different levels in various regions of the EU.

Indexed as

Patient Reported Outcome MeasuresClinical Trials as TopicEquipment and SuppliesEuropeHumansValue-Based PurchasingEuropeMedical devicePatient-reported outcomeValue-based purchasing

Identifiers

PMID31098886
PMCPMC6544589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.